<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4275">
  <stage>Registered</stage>
  <submitdate>9/01/2014</submitdate>
  <approvaldate>9/01/2014</approvaldate>
  <nctid>NCT02047461</nctid>
  <trial_identification>
    <studytitle>Safety &amp; Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP</studytitle>
    <scientifictitle>A Phase 2, Multicenter, Multinational, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of ALXN1101 in Pediatric Patients With Molybdenum Cofactor Deficiency (MoCD) Type A Currently Treated With Recombinant Escherichia Coli-derived Cyclic Pyranopterin Monophosphate (rcPMP)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-002701-56</secondaryid>
    <secondaryid>ALXN1101-MCD-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Molybdenum Cofactor Deficiency, Type A</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ALXN1101

Experimental: ALXN1101 - daily IV infusions


Treatment: drugs: ALXN1101
IV infusion

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of ALXN1101 - The type, number and frequency of adverse events and severity of adverse events (AEs) and serious adverse events (SAEs)
Change from baseline in: clinical laboratory assessments, findings on physical examination, vital sign measurements, and EEG results</outcome>
      <timepoint>First 6 months of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics parameters of ALXN1101 - Plasma concentration (Cmax), time to maximum observed plasma concentration (tmax), area under the plasma concentration-time curve (AUC), and terminal half-life (tÂ½)</outcome>
      <timepoint>First 6 months of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of ALXN1101 on urine and blood biomarkers - Change from baseline in urine and blood biomarkers.</outcome>
      <timepoint>Up to Month 66</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of ALXN1101 on neurologic function including motor examination - Change from baseline on repeated Neurologic examinations such as muscle strength and tone, as well as sensory and reflex exam.</outcome>
      <timepoint>Up to Month 66</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Long-term safety of ALXN1101 - The type, number and frequency of adverse events and serious adverse events (SAEs)
Change from baseline in: clinical laboratory assessments, findings on physical examination, vital sign measurements, and EEG results</outcome>
      <timepoint>Up to Month 66</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of ALXN1101 on cognitive functions - Change from baseline in cognitive function using age appropriate measures of cognition, eg. Wechsler Preschoool and Primary Scale of intelligence</outcome>
      <timepoint>Up to Month 66</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female patients with a genetically confirmed diagnosis of MoCD Type A (MOCS1
             mutation)

          -  Currently treated with rcPMP infusions</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Current or planned treatment with another investigational drug or device, with the
        exception rcPMP treatment through Day -1.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>7</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Tunisia</country>
      <state>Tunis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alexion Pharma GmbH</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will include a screening period, a 6-month treatment period, and a 60-month,
      long-term extension period.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02047461</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>